Diversity in Alzheimer's disease drug trials: Reflections on reporting and social construction of race

Ganesh M. Babulal, Sanne Franzen*, Erin L. Abner, Jade Emily Smith, Esther van den Berg, Monica Rivera Mindt, Rozermarijn Lidewij van Bruchem-Visser, Lon S. Schneider, Niels D. Prins, Janne M. Papma

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

4 Citations (Scopus)
Original languageEnglish
Pages (from-to)867-868
Number of pages2
JournalAlzheimer's and Dementia
Volume18
Issue number4
DOIs
Publication statusPublished - Apr 2022

Bibliographical note

ACKNOWLEDGMENTS:
F and JMP report a grant from The Netherlands Organisation forHealth Research and Development/Alzheimer’s Nederland (ZonMwMemorabel; grant number 733050834). JES reports a personalJamesB.Reynoldsscholarshipforforeignstudy.LSSreportsagrantfrom NIH (P30 AG066530). GMB reports grants from NIH/NIA(R01AG068183, R01AG067428, A2021142S) and the BrightFo-cus Foundation (A2021142S). MRM is supported by grants fromthe NIA/NIH (R13 AG071313-01, R01AG065110-01A1, NIH/NIA5U19AG024904-14, NIH/NIA R01AG066471-01A1), NIH/NIMH(U24MH100931-03), NIH/NIA (5R24AG065163), National ScienceFoundation,theGenentechHealthEquity2020Fund(G-89294),andtheAlzheimer’sAssociation(AARGD-16-446038).

Cite this